Piper Sandler assumed coverage on shares of Tempus AI (NASDAQ:TEM – Free Report) in a report published on Monday, Marketbeat reports. The firm issued a neutral rating and a $40.00 target price on the stock.
Several other brokerages also recently issued reports on TEM. Needham & Company LLC reiterated a buy rating and issued a $47.00 price target on shares of Tempus AI in a report on Wednesday, August 7th. William Blair began coverage on shares of Tempus AI in a research report on Tuesday, July 9th. They issued an outperform rating for the company. Morgan Stanley began coverage on shares of Tempus AI in a research report on Tuesday, July 9th. They issued an overweight rating and a $44.00 price objective for the company. TD Cowen began coverage on shares of Tempus AI in a research report on Tuesday, July 9th. They issued a buy rating and a $50.00 price objective for the company. Finally, Stifel Nicolaus began coverage on shares of Tempus AI in a research report on Tuesday, July 9th. They issued a buy rating and a $45.00 price objective for the company. One analyst has rated the stock with a hold rating and nine have assigned a buy rating to the stock. Based on data from MarketBeat, Tempus AI presently has a consensus rating of Moderate Buy and an average price target of $45.56.
Check Out Our Latest Analysis on TEM
Tempus AI Price Performance
Hedge Funds Weigh In On Tempus AI
Several large investors have recently modified their holdings of TEM. Sandia Investment Management LP bought a new position in Tempus AI in the second quarter worth about $136,000. Northwestern University bought a new position in Tempus AI in the second quarter worth about $491,000. Squarepoint Ops LLC bought a new position in Tempus AI in the second quarter worth about $633,000. WINTON GROUP Ltd bought a new position in Tempus AI in the second quarter worth about $634,000. Finally, EFG Asset Management North America Corp. bought a new position in Tempus AI in the second quarter worth about $1,333,000.
About Tempus AI
Tempus AI Inc is a technology company advancing precision medicine through the practical application of artificial intelligence principally in healthcare. The company provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics.
Featured Stories
- Five stocks we like better than Tempus AI
- Airline Stocks – Top Airline Stocks to Buy Now
- Brinker International’s Price Dip is an Appetizing Entry Point
- How to Effectively Use the MarketBeat Ratings Screener
- 3 Stocks That Could Beat the September Blues
- How to Invest in Tech Stocks and Top Tech Stocks to Consider
- Canopy Growth Stock: Can It Sustain Recent Gains?
Receive News & Ratings for Tempus AI Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tempus AI and related companies with MarketBeat.com's FREE daily email newsletter.